These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

302 related articles for article (PubMed ID: 36250069)

  • 1. An update on preclinical models of hereditary haemorrhagic telangiectasia: Insights into disease mechanisms.
    Arthur HM; Roman BL
    Front Med (Lausanne); 2022; 9():973964. PubMed ID: 36250069
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hereditary Haemorrhagic Telangiectasia, an Inherited Vascular Disorder in Need of Improved Evidence-Based Pharmaceutical Interventions.
    Snodgrass RO; Chico TJA; Arthur HM
    Genes (Basel); 2021 Jan; 12(2):. PubMed ID: 33513792
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Overexpression of Activin Receptor-Like Kinase 1 in Endothelial Cells Suppresses Development of Arteriovenous Malformations in Mouse Models of Hereditary Hemorrhagic Telangiectasia.
    Hwan Kim Y; Vu PN; Choe SW; Jeon CJ; Arthur HM; Vary CPH; Lee YJ; Oh SP
    Circ Res; 2020 Oct; 127(9):1122-1137. PubMed ID: 32762495
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Emerging roles of BMP9 and BMP10 in hereditary hemorrhagic telangiectasia.
    Tillet E; Bailly S
    Front Genet; 2014; 5():456. PubMed ID: 25620979
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BMP10 functions independently from BMP9 for the development of a proper arteriovenous network.
    Choi H; Kim BG; Kim YH; Lee SJ; Lee YJ; Oh SP
    Angiogenesis; 2023 Feb; 26(1):167-186. PubMed ID: 36348215
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Arterial endoglin does not protect against arteriovenous malformations.
    Singh E; Redgrave RE; Phillips HM; Arthur HM
    Angiogenesis; 2020 Nov; 23(4):559-566. PubMed ID: 32506200
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Endoglin and activin receptor-like-kinase 1 are co-expressed in the distal vessels of the lung: implications for two familial vascular dysplasias, HHT and PAH.
    Mahmoud M; Borthwick GM; Hislop AA; Arthur HM
    Lab Invest; 2009 Jan; 89(1):15-25. PubMed ID: 19015642
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mutations in the ENG, ACVRL1, and SMAD4 genes and clinical manifestations of hereditary haemorrhagic telangiectasia: experience from the Center for Osler's Disease, Uppsala University Hospital.
    Karlsson T; Cherif H
    Ups J Med Sci; 2018 Sep; 123(3):153-157. PubMed ID: 30251589
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Brain arteriovenous malformation in hereditary hemorrhagic telangiectasia: Recent advances in cellular and molecular mechanisms.
    Drapé E; Anquetil T; Larrivée B; Dubrac A
    Front Hum Neurosci; 2022; 16():1006115. PubMed ID: 36504622
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Common and distinctive pathogenetic features of arteriovenous malformations in hereditary hemorrhagic telangiectasia 1 and hereditary hemorrhagic telangiectasia 2 animal models--brief report.
    Garrido-Martin EM; Nguyen HL; Cunningham TA; Choe SW; Jiang Z; Arthur HM; Lee YJ; Oh SP
    Arterioscler Thromb Vasc Biol; 2014 Oct; 34(10):2232-6. PubMed ID: 25082229
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SMAD4 Prevents Flow Induced Arteriovenous Malformations by Inhibiting Casein Kinase 2.
    Ola R; Künzel SH; Zhang F; Genet G; Chakraborty R; Pibouin-Fragner L; Martin K; Sessa W; Dubrac A; Eichmann A
    Circulation; 2018 Nov; 138(21):2379-2394. PubMed ID: 29976569
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhanced responses to angiogenic cues underlie the pathogenesis of hereditary hemorrhagic telangiectasia 2.
    Choi EJ; Kim YH; Choe SW; Tak YG; Garrido-Martin EM; Chang M; Lee YJ; Oh SP
    PLoS One; 2013; 8(5):e63138. PubMed ID: 23675457
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Executive summary of the 14th HHT international scientific conference.
    Ola R; Hessels J; Hammill A; Friday C; Clancy M; Al-Samkari H; Meadows S; Iyer V; Akhurst R
    Angiogenesis; 2023 Aug; 26(Suppl 1):27-37. PubMed ID: 37695357
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Endoglin and alk1 as therapeutic targets for hereditary hemorrhagic telangiectasia.
    Ruiz-Llorente L; Gallardo-Vara E; Rossi E; Smadja DM; Botella LM; Bernabeu C
    Expert Opin Ther Targets; 2017 Oct; 21(10):933-947. PubMed ID: 28796572
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Estrogen therapy for hereditary haemorrhagic telangiectasia (HHT): Effects of raloxifene, on Endoglin and ALK1 expression in endothelial cells.
    Albiñana V; Bernabeu-Herrero ME; Zarrabeitia R; Bernabéu C; Botella LM
    Thromb Haemost; 2010 Mar; 103(3):525-34. PubMed ID: 20135064
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-angiogenic therapeutic strategies in hereditary hemorrhagic telangiectasia.
    Ardelean DS; Letarte M
    Front Genet; 2015; 6():35. PubMed ID: 25717337
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SMAD4 Deficiency Leads to Development of Arteriovenous Malformations in Neonatal and Adult Mice.
    Kim YH; Choe SW; Chae MY; Hong S; Oh SP
    J Am Heart Assoc; 2018 Nov; 7(21):e009514. PubMed ID: 30571376
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Potential Second-Hits in Hereditary Hemorrhagic Telangiectasia.
    Bernabeu C; Bayrak-Toydemir P; McDonald J; Letarte M
    J Clin Med; 2020 Nov; 9(11):. PubMed ID: 33167572
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Microphysiological HHT-on-a-Chip Platform Recapitulates Patient Vascular Lesions.
    Fang JS; Hatch CJ; Andrejecsk J; Trigt WV; Juat DJ; Chen YH; Matsumoto S; Lee AP; Hughes CCW
    bioRxiv; 2024 Mar; ():. PubMed ID: 38559155
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential Expression of Circulating Plasma miRNA-370 and miRNA-10a from Patients with Hereditary Hemorrhagic Telangiectasia.
    Ruiz-Llorente L; Albiñana V; Botella LM; Bernabeu C
    J Clin Med; 2020 Sep; 9(9):. PubMed ID: 32899377
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.